Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03621722 · ClinicalTrials.gov registry record · NA
AroMatherapy for Blood and Marrow Transplant PatIENTs (AMBIENT)
A NA study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03621722: Completed NA study, sponsored by Hackensack Meridian Health.
NCT03621722 is a NA study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03621722, a NA study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
The study is comparing the difference between the use of Elequil Aromatabs versus standard of care practice treatments on Blood Marrow Transplantation patients.
Primary Outcome
Differences in the severity of nausea and vomiting between patients in the treatment and control groups
Interventions
- OTHER Elequil Aromatabs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-02-27 |
| Est. Completion | 2019-12-31 |
| Phase | NA |
What the finished NCT03621722 record still lists
NCT03621722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Elequil Aromatabs is the first listed.
NCT03621722 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03621722 about?
NCT03621722 is a clinical study titled "AroMatherapy for Blood and Marrow Transplant PatIENTs (AMBIENT)". The study is comparing the difference between the use of Elequil Aromatabs versus standard of care practice treatments on Blood Marrow Transplantation patients.
What is the current status of trial NCT03621722?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-02-27. Estimated completion is 2019-12-31.
What interventions are being tested in trial NCT03621722?
The interventions under investigation include: Elequil Aromatabs (OTHER).
Who is sponsoring clinical trial NCT03621722?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03621722's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI